image credit- shutterstock
US-based BostonGene, the developer of the leading AI model for tumour and immune biology, has announced a strategic research partnership with Japan-based Kyoto University, a research institution known for its groundbreaking advancements in medicine and science.
The partnership supports a multicenter, Phase II clinical trial led by Dr Manabu Muto of Kyoto University, evaluating the safety and efficacy of a combined therapeutic approach using immune checkpoint inhibitors (ICI) and photodynamic therapy (PDT) for patients facing advanced gastrointestinal cancers.
The study is being conducted as an investigator-initiated trial with financial support from Meiji Seika Pharma.
BostonGene will apply its multimodal AI analytics platform to integrate genomic, transcriptomic, immune, and clinical data generated through the study, identifying molecular signatures and immune-response patterns associated with therapeutic response and resistance to establish a biologically grounded framework for future patient stratification and combination therapy development.
Insights generated through this study are expected to support future clinical trial design decisions, biomarker-driven patient selection strategies, and broader for development efforts involving combination immunotherapy approaches.
